-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 7, Qilu Pharmaceuticals applied for the 4 types of generic listing applications for emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
At present, there are only original research in China.
Drugs were approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
.
According to data from Menet.
com, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
On June 7, Qilu Pharmaceuticals applied for the 4 types of generic listing applications for emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
At present, there are only original research in China.
Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
.
According to data from Menet.
com, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
